Home > News > pSivida looks to advance in US market
March 17th, 2005
pSivida looks to advance in US market
Australian biotech pSivida is looking to boost its profile in the United States as it pushes its new silicon-based drug delivery technology, designed to substantially reduce side-effects in patients.
Speaking at a shareholders briefing in Sydney pSivida managing director Gavin Rezos said shrinking consumer tolerance for drug side effects over the past two decades had made its BioSilicon technology very lucrative.
Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014
NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014
SentiMag® Now Available in Australia and New Zealand July 21st, 2014
More than glitter: Scientists explain how gold nanoparticles easily penetrate cells, making them useful for delivering drugs July 21st, 2014
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010